Cargando…

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Detalles Bibliográficos
Autores principales:	Kunzke, Thomas, Hölzl, Fabian T., Prade, Verena M., Buck, Achim, Huber, Katharina, Feuchtinger, Annette, Ebert, Karolin, Zwingenberger, Gwen, Geffers, Robert, Hauck, Stefanie M., Haffner, Ivonne, Luber, Birgit, Lordick, Florian, Walch, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473480/ https://www.ncbi.nlm.nih.gov/pubmed/34586736 http://dx.doi.org/10.1002/ctm2.547

Ejemplares similares

De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry
por: Prade, Verena M., et al.
Publicado: (2020)

Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF
por: Ebert, Karolin, et al.
Publicado: (2022)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
por: Keller, Simone, et al.
Publicado: (2018)

MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
por: Ebert, Karolin, et al.
Publicado: (2019)

Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome
por: Kunzke, Thomas, et al.
Publicado: (2017)

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
por: Ebert, Karolin, et al.
Publicado: (2020)

Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
por: Ebert, Karolin, et al.
Publicado: (2020)

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)

Spatial metabolomics reveals upregulation of several pyrophosphate-producing pathways in cortical bone of Hyp mice
por: Buck, Achim, et al.
Publicado: (2022)

A simple preparation step to remove excess liquid lipids in white adipose tissue enabling improved detection of metabolites via MALDI-FTICR imaging MS
por: Wang, Qian, et al.
Publicado: (2022)

Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction
por: Kunzke, Thomas, et al.
Publicado: (2019)

Spatial metabolomics for evaluating response to neoadjuvant therapy in non‐small cell lung cancer patients
por: Shen, Jian, et al.
Publicado: (2022)

Patterns of Carbon-Bound Exogenous Compounds Impact Disease Pathophysiology in Lung Cancer Subtypes in Different Ways
por: Shen, Jian, et al.
Publicado: (2023)

MALDI Mass Spectrometry Imaging—Prognostic Pathways and Metabolites for Renal Cell Carcinomas
por: Erlmeier, Franziska, et al.
Publicado: (2022)

Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
por: Kolbe, Katharina, et al.
Publicado: (2022)

Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma
por: Wang, Jun, et al.
Publicado: (2023)

The synergism of spatial metabolomics and morphometry improves machine learning‐based renal tumour subtype classification
por: Prade, Verena M., et al.
Publicado: (2022)

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines
por: Raimúndez, Elba, et al.
Publicado: (2020)

Light sheet fluorescence microscopy guided MALDI-imaging mass spectrometry of cleared tissue samples
por: Blutke, Andreas, et al.
Publicado: (2020)

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
por: Haffner, Ivonne, et al.
Publicado: (2021)

Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv(max)) In Laryngeal and Hypopharyngeal Cancer
por: Werner, Jonas, et al.
Publicado: (2019)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Prognostic impact of pretherapeutic gamma-glutamyltransferase on patients with nasopharyngeal carcinoma
por: Wen, Yue-Feng, et al.
Publicado: (2017)

Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer
por: Le Thiec, Maelle, et al.
Publicado: (2020)

Examining the blood amino acid status in pretherapeutic patients with hyperphenylalaninemia
por: Liang, Lili, et al.
Publicado: (2019)

Elbow Stiffness Imaging: A Practical Diagnostic and Pretherapeutic Approach
por: Lombard, Charles, et al.
Publicado: (2021)

The Influence of Pretherapeutic and Preoperative Sarcopenia on Short-Term Outcome after Esophagectomy
por: Grün, Johanna, et al.
Publicado: (2020)

Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy
por: Lai, Sicong, et al.
Publicado: (2020)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma
por: Hofbauer, S L, et al.
Publicado: (2014)

Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC
por: Apostolova, Ivayla, et al.
Publicado: (2014)

Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer
por: Staudigl, Christine, et al.
Publicado: (2015)

Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma
por: Friedl, Marlene, et al.
Publicado: (2022)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer
por: Huber, Michaela C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kh0va28vtehm1v1ono48mvgpse